PIK3CA and rectal cancer: Our study provides evidence for the benefits of concurrent aspirin use with neoadjuvant CRT for rectal cancer, which appears to be independent from tumor PIK3CA mutation status, suggesting a broader indication for aspirin in this clinical setting.